The societal burden of HIV/AIDS in Northern Italy: An analysis of costs and quality of life

被引:16
作者
Hubben, G. A. A. [1 ]
Bishai, D. [2 ]
Pechlivanoglou, P. [1 ]
Cattelan, A. M. [3 ]
Grisetti, R. [4 ]
Facchin, C. [5 ]
Compostella, F. A.
Bos, J. M. [1 ]
Postma, M. J. [1 ]
Tramarin, A. [6 ]
机构
[1] Univ Groningen, Univ Ctr Pharm, Groningen, Netherlands
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Infect Dis Ward, OC Rovigo, Italy
[4] Fdn Sacra Famiglia, Milan, Italy
[5] Univ Padua, Sch Infect Dis, I-35100 Padua, Italy
[6] Agenzia Reg Socio Sanitaria Reg Veneto, Venice, Italy
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2008年 / 20卷 / 04期
关键词
HIV AIDS care; direct costs; indirect costs; quality of life; Italy;
D O I
10.1080/09540120701867107
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This study aims to measure the direct and indirect costs of HIV/AIDS care and quality of life (QoL) of HIV-infected patients in Northern Italy. We conducted a prospective cohort study over 12 months, enrolling a sample of 121 patients with HIV infection from two cities in Northern Italy. Patients were surveyed at baseline and were followed-up at 6 and 12 months. To assess the relationship between costs and stage of disease, patients were categorized into three groups at baseline: "No HAART" (asymptomatic and never before on highly active antiretroviral therapy (HAART)), "Stable HAART" (HAART with mild HIV infection and no prior opportunistic infections) and "HAART failure" (primary HAART regimen was altered because of severe side effects or immunological failure). Direct medical costs were based on utilization of (day) hospital admissions, diagnostic procedures, laboratory tests, clinic visits, consultations and antiretroviral drug use. Indirect costs included production losses due to absence from work, reduced productivity at work and reduced unpaid labour participation. QoL was assessed by visual analogue scale. Parametric regression was used to estimate the expected value and the standard deviation of annual costs per patient. The expected value of total annual costs was is an element of 1818 and is an element of 9820 and is an element of 12,332, for groups "No HAART", "Stable HAART" and "HAART failure" respectively. We estimated annual expected earnings as is an element of 14,994 and is an element of 10,811 and is an element of 9820 for the same respective groups. The expected value of QoL on a scale of 0-1 in these same patient groups was 0.80, 0.78 and 0.64. We conclude that indirect costs contribute substantially to total costs and are comparable in magnitude to the direct costs excluding antiretroviral drugs. The costs of inpatient care in our cohort were almost negligible compared to total costs. Despite being in treatment, many patients were still gainfully employed and generated substantial expected annual earnings.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 24 条
[1]   Comparing alternative models: log vs Cox proportional hazard? [J].
Basu, A ;
Manning, WG ;
Mullahy, J .
HEALTH ECONOMICS, 2004, 13 (08) :749-765
[2]  
Drummond MF, 2005, METHODS EC EVALUATIO
[3]  
*EUR, 2004, EUR DAT
[4]   Beta regression for modelling rates and proportions [J].
Ferrari, SLP ;
Cribari-Neto, F .
JOURNAL OF APPLIED STATISTICS, 2004, 31 (07) :799-815
[5]   Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy [J].
Garattini, L ;
Tediosi, F ;
Di Cintio, E ;
Yin, D ;
Parazzini, F .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2001, 13 (06) :733-741
[6]   Costs of HIV medical care in the era of highly active antiretroviral therapy [J].
Gebo, KA ;
Chaisson, RE ;
Folkemer, JG ;
Bartlett, JG ;
Moore, RD .
AIDS, 1999, 13 (08) :963-969
[7]  
Kalbfleisch JD., 2002, STAT ANAL FAILURE TI
[8]   The direct costs of HIV/AIDS care [J].
Levy, AR ;
James, D ;
Johnston, KM ;
Hogg, RS ;
Harrigan, PR ;
Harrigan, BP ;
Sobolev, B ;
Montaner, JS .
LANCET INFECTIOUS DISEASES, 2006, 6 (03) :171-177
[9]  
*MIN SAL, 2004, TA REG ANN 2004 REM
[10]   Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study [J].
Mocroft, A ;
Monforte, AD ;
Kirk, O ;
Johnson, MA ;
Friis-Moller, N ;
Banhegyi, D ;
Blaxhult, A ;
Mulcahy, F ;
Gatell, JM ;
Lundgren, JD .
HIV MEDICINE, 2004, 5 (06) :437-447